Salix Company profile

Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include XIFAXAN tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; APRISO for the maintenance of remission of ulcerative colitis in adults; MOVIPREP and OSMOPREP, which are used for cleansing of the colon as a preparation for colonoscopy in adults; METOZOLV ODT that orally disintegrating tablets used as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease. Its products also include AZASAN, which is used as an adjunct for the prevention of rejection in renal homotransplantations, and for the management of active rheumatoid arthritis to reduce signs and symptoms; VISICOL tablets for cleansing of the colon as a preparation for colonoscopy; and ANUSOL-HC and PROCTOCORT for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic Ulcerative Colitis, cryptitis, and other inflammatory conditions of the anorectum and pruritis ani. In addition, the company provides DIURIL for the treatment of high blood pressure and also as adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. Further, it has various product candidates under development for the treatment of irritable bowel syndrome, HIV-associated diarrhea, ulcerative colitis, and ulcerative proctitis, and Opioid induced constipation. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.